Question to the Cabinet Office:

To ask the Minister for the Cabinet Office, whether Jonathan Powell has held meetings with Grandview Institution since November 2024.

Answered by Dan Jarvis - Minister of State (Cabinet Office)

The National Security Adviser meets with a range of individuals and organisations as part of his role providing advice to the Prime Minister and the Cabinet on national security matters. Such meetings are often sensitive in nature, and the Government does not routinely comment on them or their content.

Question to the Foreign, Commonwealth & Development Office:

To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what assessment she has made of the potential impact of China’s Law on Promoting Ethnic Unity and Progress on freedom of religion and belief for (a) Tibetans, (b) Uyghurs, (c) Hui and (d) Mongols; and what discussions she has had with international counterparts on that law.

Answered by Seema Malhotra - Parliamentary Under-Secretary (Foreign, Commonwealth and Development Office)

I refer the Rt Hon Member to the answer provided in the House of Lords on 17 March in response to Question HL15305.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment have they made of the proportion of newly diagnosed glioblastoma patients who receive the full standard of care on the NHS.

Answered by Sharon Hodgson - Parliamentary Under-Secretary (Department of Health and Social Care)

The Government recognises that there are currently limited treatment options available for people who have been diagnosed with cancerous brain tumours, such as glioblastoma, and recognises the significant impact that this rare cancer can have on outcomes and experiences of care.

Several steps are being taken to improve outcomes for glioblastoma patients.

In January 2026, the National Institute for Health and Care Research (NIHR) announced increased investment of over £25 million in the NIHR Brain Tumour Research Consortium. The world-leading consortium aims to transform outcomes for adults and children and their families who are living with brain tumours, ultimately reducing lives lost to cancer. In addition to speeding up diagnosis and treatment, the work being undertaken by the consortium aims to ensure that patients have access to the latest treatments and technology and to clinical trials. This will make a significant contribution to bringing the United Kingdom’s cancer survival rates back up to the standards of the best in the world.

In February 2026, the Department published the National Cancer Plan for England which sets out how patients with rare cancers, including glioblastoma, will benefit from a move to specialist multi-disciplinary teams which cover multiple healthcare providers. This will allow them to benefit from the input of specialist centres and access to the best evidence-based care. To accelerate breakthroughs, the Government will explore innovative procurement methods, such as advance market commitments, to stimulate the development of new diagnostic tests, targeted therapies, and more effective treatments for rare cancers, such as brain tumours.

The Department recognises that cancer outcomes remain poorest in some deprived, rural, and coastal areas. To support improvement, the Government has provided £200 million of ring‑fenced funding for Cancer Alliances in 2026/27 to improve cancer pathway performance and reduce delays. The Department monitors progress through regular oversight with NHS England, tracking improvements in early diagnosis and treatment standards across regions. These measures underpin our commitment to reducing geographic disparities so that a patient’s chances of survival do not depend on where they live.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment have they made of the number of British glioblastoma patients who have sought alternative treatment overseas in each of the last 5 years.

Answered by Sharon Hodgson - Parliamentary Under-Secretary (Department of Health and Social Care)

The Government recognises that there are currently limited treatment options available for people who have been diagnosed with cancerous brain tumours, such as glioblastoma, and recognises the significant impact that this rare cancer can have on outcomes and experiences of care.

Several steps are being taken to improve outcomes for glioblastoma patients.

In January 2026, the National Institute for Health and Care Research (NIHR) announced increased investment of over £25 million in the NIHR Brain Tumour Research Consortium. The world-leading consortium aims to transform outcomes for adults and children and their families who are living with brain tumours, ultimately reducing lives lost to cancer. In addition to speeding up diagnosis and treatment, the work being undertaken by the consortium aims to ensure that patients have access to the latest treatments and technology and to clinical trials. This will make a significant contribution to bringing the United Kingdom’s cancer survival rates back up to the standards of the best in the world.

In February 2026, the Department published the National Cancer Plan for England which sets out how patients with rare cancers, including glioblastoma, will benefit from a move to specialist multi-disciplinary teams which cover multiple healthcare providers. This will allow them to benefit from the input of specialist centres and access to the best evidence-based care. To accelerate breakthroughs, the Government will explore innovative procurement methods, such as advance market commitments, to stimulate the development of new diagnostic tests, targeted therapies, and more effective treatments for rare cancers, such as brain tumours.

The Department recognises that cancer outcomes remain poorest in some deprived, rural, and coastal areas. To support improvement, the Government has provided £200 million of ring‑fenced funding for Cancer Alliances in 2026/27 to improve cancer pathway performance and reduce delays. The Department monitors progress through regular oversight with NHS England, tracking improvements in early diagnosis and treatment standards across regions. These measures underpin our commitment to reducing geographic disparities so that a patient’s chances of survival do not depend on where they live.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what plans do they have to tackle geographical disparities when it comes to the treatment of glioblastoma.

Answered by Sharon Hodgson - Parliamentary Under-Secretary (Department of Health and Social Care)

The Government recognises that there are currently limited treatment options available for people who have been diagnosed with cancerous brain tumours, such as glioblastoma, and recognises the significant impact that this rare cancer can have on outcomes and experiences of care.

Several steps are being taken to improve outcomes for glioblastoma patients.

In January 2026, the National Institute for Health and Care Research (NIHR) announced increased investment of over £25 million in the NIHR Brain Tumour Research Consortium. The world-leading consortium aims to transform outcomes for adults and children and their families who are living with brain tumours, ultimately reducing lives lost to cancer. In addition to speeding up diagnosis and treatment, the work being undertaken by the consortium aims to ensure that patients have access to the latest treatments and technology and to clinical trials. This will make a significant contribution to bringing the United Kingdom’s cancer survival rates back up to the standards of the best in the world.

In February 2026, the Department published the National Cancer Plan for England which sets out how patients with rare cancers, including glioblastoma, will benefit from a move to specialist multi-disciplinary teams which cover multiple healthcare providers. This will allow them to benefit from the input of specialist centres and access to the best evidence-based care. To accelerate breakthroughs, the Government will explore innovative procurement methods, such as advance market commitments, to stimulate the development of new diagnostic tests, targeted therapies, and more effective treatments for rare cancers, such as brain tumours.

The Department recognises that cancer outcomes remain poorest in some deprived, rural, and coastal areas. To support improvement, the Government has provided £200 million of ring‑fenced funding for Cancer Alliances in 2026/27 to improve cancer pathway performance and reduce delays. The Department monitors progress through regular oversight with NHS England, tracking improvements in early diagnosis and treatment standards across regions. These measures underpin our commitment to reducing geographic disparities so that a patient’s chances of survival do not depend on where they live.

Found: of SLAPPs on free speech Mr Alistair Carmichael: Fishing industry Blair McDougall and Sir Iain Duncan Smith

Found: and the February 2026 recess, four MPs made 5 representations to BBCOM (Bambos Charalambous, Iain Duncan Smith

Found: * update or new entry.43 DEPARTMENT FOR WORK AND PENSIONS Rt Hon Iain Duncan Smith MP, Secretary

Found: cell">Department for Work and Pensions

Found: cell">Department for Work and Pensions

Found: Charities Life Fellow, Cancer Research UK. 43 DEPARTMENT FOR WORK AND PENSIONS Rt Hon Iain Duncan Smith

Found: * update or new entry. 47 DEPARTMENT FOR WORK AND PENSIONS Rt Hon Iain Duncan Smith MP

Found: 40 DEPARTMENT FOR WORK AND PENSIONS Rt Hon Iain Duncan Smith

Found: cell">Department for Work and Pensions